Swipe om te navigeren naar een ander artikel
To assess the validity of the Patient Activation Measure (PAM13) of patient activation in persons with neurological conditions.
“The Everyday Experience of Living with and Managing a Neurological Condition” (The LINC study) surveyed 948 adults with neurological conditions residing in Canada in 2011 and 2012. Using data for 722 respondents who met coding requirements for the PAM-13, we examined the properties of the measure using principle components analysis, inter-item correlations and Cronbach’s alpha to assess unidimensionality and internal consistency. Rasch modeling was used to assess item performance and scaling. Construct validity was assessed by calculating associations between the PAM and known correlates.
PAM-13 provides a suitably reliable and valid instrument for research in patients with neurological conditions, but scaling problems may yield measurement error and biases for those with low levels of activation. This is of particular importance when used in clinical settings or for individual client care. Our study also suggests that measurement of activation may benefit from tailoring items and scaling to specific diagnostic groups such as people with neurological conditions, thus allowing the PAM-13 to recognize unique attributes and management challenges in those conditions.
The PAM-13 is an internally reliable and valid tool for research purposes. The use of categorical activation “level” in clinical settings should be done with caution.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Hibbard, J. H., & Greene, J. (2013). What the evidence shows about patient activation: Better health outcomes and care experiences; fewer data on costs. Health Affairs (Millwood), 32(2), 207–214. CrossRef
Wagner, E. H. (1998). Chronic disease management: What will it take to improve care for chronic illness? Effective clinical practice, 1(1), 2–4. PubMed
Barr, V. J., Robinson, S., Marin-Link, B., Underhill, L., Dotts, A., Ravensdale, D., et al. (2003). The expanded chronic care model: An integration of concepts and strategies from population health promotion and the chronic care model. Hospital Quarterly, 7(1), 73–82. PubMed
Fowles, J. B., Terry, P., Xi, M., Hibbard, J., Bloom, C. T., & Harvey, L. (2009). Measuring self-management of patients’ and employees’ health: Further validation of the patient activation measure (PAM) based on its relation to employee characteristics. Patient Education and Counseling, 77(1), 116–122. PubMedCrossRef
Kaplan, R. M., Anderson, J. P., Wu, A. W., Mathews, W. C., Kozin, F., & Orenstein, D. (1989). The quality of well-being scale. Applications in AIDS, cystic fibrosis, and arthritis. Medical Care, 27(3 Suppl.), 27–43. CrossRef
Hibbard, J. H., & Cunningham, P. J. (2008). How engaged are consumers in their health and health care, and why does it matter? Res Briefs, 8, 1–9.
Insignia Health. (2011). Patient activation measure ( PAM) 13™ License Materials copyright Insignia Health, LLC.
Brenk-Franz, K., Hibbard, J. H., Herrmann, W. J., Freund, T., Szecsenyi, J., Djalali, S., et al. (2013). Validation of the German version of the patient activation measure 13 (PAM13-D) in an international multicentre study of primary care patients. PLoS One, 8(9), e74786. PubMedCentralPubMedCrossRef
Zill, J. M., Dwinger, S., Kriston, L., Rohenkohl, A., Harter, M., & Dirmaier, J. (2013). Psychometric evaluation of the German version of the patient activation measure (PAM13). BMC Public Health, 13, 1027-2458-13-1027. CrossRef
Maindal, H. T., Sandbaek, A., Kirkevold, M., & Lauritzen, T. (2011). Effect on motivation, perceived competence, and activation after participation in the “Ready to Act” programme for people with screen-detected dysglycaemia: A 1-year randomised controlled trial, Addition-DK. Scandinavian Journal of Public Health, 39(3), 262–271. PubMedCrossRef
Cook, D. A., & Beckman, T. J. (2006). Current concepts in validity and reliability for psychometric instruments: Theory and application. The American Journal of Medicine, 119(2), 166.e7-166.16. CrossRef
Versnel, J., Packer, T., Weeks, L. E., Brown, J., Godwin, M., Hutchinson, S., et al. (2013). The everyday experience of living with and managing a neurological condition (the LINC study): Study design. BMC Neurology, 13, 30-2377-13-30. CrossRef
Caesar-Chavannes, C. R., & MacDonald, S. (2013). Cross-Canada forum—National Population Health Study of neurological conditions in Canada. Chronic Diseases Injuries in Canada, 33(3), 188–191. PubMed
Statistics Canada. (2009). User guide 2007–2008 microdata files. Canadian Community Health Survey (CCHS)—Annual Component. Ottawa: Statistics Canada.
Jenkinson, C., Hobart, J., Chandola, T., Fitzpatrick, R., Peto, V., Swash, M., et al. (2002). Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: Tests of data quality, score reliability, response rate and scaling assumptions. Journal of Neurology, 249(2), 178–183. PubMedCrossRef
Marra, C. A., Woolcott, J. C., Kopec, J. A., Shojania, K., Offer, R., Brazier, J. E., et al. (2005). A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Social Science and Medicine, 60(7), 1571–1582. PubMedCrossRef
Feng, Y., Bernier, J., McIntosh, C., & Orpana, H. (2009). Validation of disability categories derived from Health Utilities Index Mark 3 scores. Health Reports, 20(2), 43–50. PubMed
R Development Core Team. (2006). R: A language and environment for statistical computing. Vienna: R Development Core Team.
Mair, P., & Hatzinger, R. (2006). eRm; extended Rasch models. R package version 0. 3. 2. http://CRAN.R-project.org/. (Accessed October 2013).
Mair, P., & Hatzinger, R. (2007). CML based estimation of extended Rasch models with the eRm package in R. Psychology Science, 49(1), 26–43.
Hattie, J. (1985). Methodology review: Assessing unidimensionality of tests and items. Applied Psychological Measurement, 9(2), 139–164. CrossRef
World Health Organization. (2003). Adherence to long-term therapies: Evidence for action (p. 12). Geneva: World Health Organization.
- The Patient Activation Measure: a validation study in a neurological population
Tanya L. Packer
- Springer International Publishing